Several studies demonstrated that CPXM2, FGF2 and NOVA1 might be available biomarkers for cancers such as hepatocellular carcinoma (HCC) [46], ovarian cancer (OC) [47] and non-small cell lung cancer [48]. Here, FGF2 is linked to non-small cell lung carcinoma.